These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2493230)

  • 21. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Islam S; Oh H; Jalal S; Karpati F; Ciofu O; Høiby N; Wretlind B
    Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pseudomonas aeruginosa and imipenem: correlation between membrane protein D2 and resistance in fifteen strains isolated from patients with mucoviscidosis].
    Recule C; Hirtz P; Le Noc P; Croizé J
    Pathol Biol (Paris); 1992 May; 40(5):433-9. PubMed ID: 1495825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas].
    Moreva TV; Anisimova LA; Erova TE; Boronin AM
    Antibiot Khimioter; 1992 Apr; 37(4):25-8. PubMed ID: 1417311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ciprofloxacin-resistant Pseudomonas keratitis.
    Garg P; Sharma S; Rao GN
    Ophthalmology; 1999 Jul; 106(7):1319-23. PubMed ID: 10406614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.
    Raja NS; Singh NN
    J Microbiol Immunol Infect; 2007 Feb; 40(1):45-9. PubMed ID: 17332906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    Hurley JC; Miller GH; Smith AL
    Diagn Microbiol Infect Dis; 1995 Aug; 22(4):331-6. PubMed ID: 8582138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of continuous exposure to ciprofloxacin on the outer membrane of P. aeruginosa.
    Magni A; Giordano A; Papa F; de Vito D; Cipriani P
    New Microbiol; 1994 Oct; 17(4):307-12. PubMed ID: 7861986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of Amikacin Hyper-Resistant Pseudomonas aeruginosa After Stepwise Exposure to High Amikacin Concentrations.
    Amábile-Cuevas CF
    Microb Drug Resist; 2017 Jan; 23(1):32-36. PubMed ID: 27183474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypes of isolates of Pseudomonas aeruginosa in a diabetes care center.
    Muthu SE; Aberna RA; Mohan V; Premalatha G; Srinivasan RS; Thyagarajan SP; Rao UA
    Arch Med Res; 2006 Jan; 37(1):95-101. PubMed ID: 16314193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of aztreonam-netilmicin association on outer membrane proteins of P. aeruginosa strains.
    Cipriani P; Giordano A; Magni A; Filadoro F
    Microbiologica; 1991 Oct; 14(4):301-5. PubMed ID: 1663572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug-resistance patterns of clinical isolates of Pseudomonas aeruginosa in regard to their lipopolysaccharide-chain sizes].
    Hasegawa M; Kobayashi I; Saika T; Nishida M
    Kansenshogaku Zasshi; 1996 Jun; 70(6):605-12. PubMed ID: 8741710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmid mediated amikacin resistance in clinical isolates of Pseudomonas aeruginosa.
    Shahid M; Malik A
    Indian J Med Microbiol; 2004; 22(3):182-4. PubMed ID: 17642729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pseudomonas aeruginosa sepsis caused by an intravenous catheter and successfully treated with amikacin].
    Sellen Crombet J; Aguirregabiria Ruíz L; Sánchez Casas A
    Rev Cubana Med Trop; 1979; 31(3):245-50. PubMed ID: 121616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of lipopolysaccharide (LPS) from impermeability-type drug resistant Pseudomonas aeruginosa using new, highly-sensitive LPS staining method].
    O'Hara K; Fukuda H; Nakahara H; Bryan LE
    Jpn J Antibiot; 1994 Oct; 47(10):1344-7. PubMed ID: 7528823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody to an aminoglycoside-resistance factor from Pseudomonas aeruginosa.
    Norris SA; Sciortino CV
    J Infect Dis; 1988 Dec; 158(6):1324-8. PubMed ID: 3143766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
    Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity.
    Tateda K; Ishii Y; Hirakata Y; Matsumoto T; Ohno A; Yamaguchi K
    J Antimicrob Chemother; 1994 Dec; 34(6):931-42. PubMed ID: 7730236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amikacin resistance developing in patients with Pseudomonas aeruginosa bronchopneumonia.
    Amirak ID; Williams RJ; Noone P; Wills MR
    Lancet; 1977 Mar; 1(8010):537-8. PubMed ID: 65626
    [No Abstract]   [Full Text] [Related]  

  • 40. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.
    Chamberland S; Bayer AS; Schollaardt T; Wong SA; Bryan LE
    Antimicrob Agents Chemother; 1989 May; 33(5):624-34. PubMed ID: 2502066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.